摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(5'-azido-2',5'-dideoxy-β-D-threo-pentofuranosyl)thymine

中文名称
——
中文别名
——
英文名称
1-(5'-azido-2',5'-dideoxy-β-D-threo-pentofuranosyl)thymine
英文别名
1-[(2R,4R,5R)-5-(azidomethyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
1-(5'-azido-2',5'-dideoxy-β-D-threo-pentofuranosyl)thymine化学式
CAS
——
化学式
C10H13N5O4
mdl
——
分子量
267.244
InChiKey
GKEHVJFBPNPCKI-BWZBUEFSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    93.2
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Deoxynucleic Guanidines (DNG)- Modified Oligonucleotides and Methods of Synthesizing Deoxynucleic Guanidine Strands
    申请人:NORTHWESTERN UNIVERSITY
    公开号:US20200399304A1
    公开(公告)日:2020-12-24
    Disclosed herein are spherical nucleic acids (SNAs) comprising oligonucleotides comprising one or more modified oligonucleotides, and methods of use thereof. Also disclosed are methods of synthesizing modified oligonucleotides for use in therapeutics, including deoxynucleic guanidine (DNG)-modified oligonucleotides.
    本文披露了包含寡核苷酸的球形核酸(SNAs),其中寡核苷酸包括一个或多个修饰的寡核苷酸,并且其使用方法。还披露了用于合成用于治疗的修饰寡核苷酸的方法,包括脱氧核酸胍(DNG)修饰的寡核苷酸。
  • Novel Dideoxynucleoside Derivatives
    申请人:Kitade Yukio
    公开号:US20080064868A1
    公开(公告)日:2008-03-13
    The present invention discloses a 5′-amino-2′-fluoro-2′,5′-dideoxynucleoside derivative represented by the following formula [1]: (wherein R 1 represents a nucleic acid base which may have a protecting group; R 2 represents a hydrogen atom or a protecting group of an amino group; R 3 represents a hydrogen atom or a protecting group of a hydroxyl group); a dideoxynucleoside-insoluble carrier bound substance prepared by binding said dideoxynucleoside derivative to an insoluble carrier, and an oligonucleotide analogue into which said dideoxynucleoside derivative is introduced. The oligonucleotide analogue being introduced with a dideoxynucleoside derivative of the present invention has excellent thermal stability and also high binding affinity when duplex is formed. Also, it is anticipated that it has high resistance to nucleases. Further, the dideoxynucleoside derivative of the present invention can be used as an amidite reagent to be used for nucleic acid synthesis, and also as a starting material for solid phase synthesis of nucleic acid by binding the amidite reagent to a solid phase.
    本发明公开了由下式[1]所表示的5'-氨基-2'-氟-2',5'-二脱氧核苷衍生物(其中R1表示可能具有保护基团的核酸碱基;R2表示氢原子或氨基的保护基团;R3表示氢原子或羟基的保护基团);通过将该二脱氧核苷衍生物与不溶性载体结合而制备的二脱氧核苷载体结合物质;以及引入了该二脱氧核苷衍生物的寡核苷酸类似物。本发明引入了含有该二脱氧核苷衍生物的寡核苷酸类似物具有优异的热稳定性,当形成双链时也具有高结合亲和力。此外,预计它具有高核酸酶抵抗力。此外,本发明的二脱氧核苷衍生物可用作用于核酸合成的酰胺酯试剂,也可作为将酰胺酯试剂结合到固相上进行核酸固相合成的起始物料。
  • Nucleoside dimers analogues with a 1,2,3-triazole linkage: conjugation of floxuridine and thymidine provides novel tools for cancer treatment. Part II
    作者:Dagmara Baraniak、Daniel Baranowski、Piotr Ruszkowski、Jerzy Boryski
    DOI:10.1080/15257770.2019.1610891
    日期:2019.11.2
    Abstract The fluorinated nucleoside dimers with a 1,2,3-triazole linkage are novel compounds within the field of bioorganic chemistry. We report on the synthesis and properties of two groups of nucleoside dimers analogs possessing a different arrangement of the 1,4-disubstituted 1,2,3-triazole linkage. Based on analysis of the 3JHH, 3JH1′C2, and 3JH1′C6 we estimated conformational preferences of sugar
    摘要具有1,2,3-三唑键的氟化核苷二聚体是生物有机化学领域中的新型化合物。我们报告了具有1,4-二取代的1,2,3-三唑键的不同排列的两组核苷二聚体类似物的合成和性质。基于对3JHH,3JH1'C2和3JH1'C6的分析,我们估计了糖部分的构象偏爱和糖苷键周围的方向。这些化合物显示出中等的抗癌活性,并在三种不同的癌细胞系中进行了细胞抑制研究。
  • METHOD FOR PREPARING NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES, AND THE USE THEREOF
    申请人:UNIVERSITE VICTOR SEGALEN BORDEAUX 2
    公开号:US20140308343A1
    公开(公告)日:2014-10-16
    The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents.
    本发明涉及一种基于功能性两亲分子或大分子的纳米粒子制备方法,可选地在至少一种胆固醇类物质的存在下,使治疗剂,特别是抗肿瘤剂封装,并用于治疗剂,特别是抗肿瘤剂的输送和载荷。
  • Novel Diastereomeric Thymidine Cyclic 3′,5′-<i>threo-</i>Phosphoramidates
    作者:Darinka Katalenić、Mladen Žinić
    DOI:10.1080/07328319808004235
    日期:1998.7
    Novel diastereomeric thymidine cyclic 3',5'-threo-phosphoramidates were prepared by the treatment of 5'-azido derivative of threo-thymidine with triphenyl phosphite as well as by the treatment of the corresponding amino derivative with phenyl phosphodichloridate. Phosphoramidation of the regioisomeric 3'- and 5'-azido derivatives of erythro-thymidine by means of triphenyl phosphite afforded the open-chain 3'- and 5'-phosphoramidates. The reaction which afforded the cyclic products was assumed to proceed via the cyclic tetraoxazaphosphorane intermediates.
查看更多

同类化合物

鲁西他滨 化合物 T14195 [1,1'-联苯基]-2,3,3',4,4',5'-六醇 [(2R,3R,5S)-3-(氨基甲基)-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]N-[[(2R,3S,5R)-3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]氨基甲酸酯 9-(2-S-苯甲基-5-脱氧-2-硫代五呋喃糖基)-9H-嘌呤-6-胺 5-脱氧胸苷 5-脱氧-5-[(碘乙酰基)氨基]-胸腺嘧啶脱氧核苷 5-碘-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-2,5-二脱氧腺苷酸 5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷 5-三氟乙酰氨基-5-脱氧胸腺嘧啶脱氧核苷 5'-脱氧-5'氟胸苷 5'-脱氧-5'-{[4-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-{[3-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-[4-苯基-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(吡啶-3-基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(4-氟苯基)-(1,2,3)三唑-1-基]胸苷 5'-硫代-胸苷3',5'-二乙酸酯 5'-溴乙酰氨基-5'-脱氧胸苷 5'-氨基-5-碘-2',5'-二脱氧尿苷 2-氯-N-[[3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]乙酰胺 2,5-二脱氧腺苷 2',5'-二脱氧尿苷 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]嘧啶-2,4-二酮 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)嘧啶-2,4(1H,3H)-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)-5-碘嘧啶-2,4(1H,3H)-二酮 1-citosin-1-yl-1,2,5-trideoxy-α-L-threo-pentofuranos-4-yloxymethylphosphonic acid 9-[2,5-dideoxy-2-fluoro-5-[N-(N-2-hydroxybenzoyl)sulfamoyl]amino-β-D-ribofuranosyl]adenine triethylammonium salt 5'-amino-2',5'-dideoxy-2'-fuorouridine 1-(5'-deoxythymidin-5'-yl)-4-[methyloxycarbonyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 2',5'-dideoxy-2'-(3,5-dimethoxybenzamido)-5'-(cyclohexylacetamido)adenosine 2',5'-dideoxy-2'-(3'',5''-dimethoxybenzamido)-5'-(diphenylacetamido)adenosine 2',5'-dideoxy-5'-(hydroxyethylthio)adenosine 1-(5-azido-2,5-dideoxy-2-fluoro-β-D-arabinofuranosyl)-5-ethyluracil 1-(5'-deoxythymidin-5'-yl)-4-[methyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 4′-C-azidomethyl-2′-deoxy-2′-fluorouridine 2',5'-dideoxy-6-thioguanosine thymidylyl (3'-5') 5'-seleno-5'-deoxythymidine 3'-O-(t-butyldimethylsilyl)-4'-α-methylthymidine (E)- and (Z)-5-(2-bromovinyl)-1-(5-chloro-2,5-dideoxy-β-D-erythro-pentofuranosyl)-5-methyl-4-(1,2,4-triazol-1-yl)pyrimidin-2(1H)-one N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>succinamic acid N-butyl-N'-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranose-5-yl>maleamide N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>maleamic acid 4'-chloromethyl-2'-deoxy-2',2'-difluorocytidine 4'-chloromethyl-2'-deoxy-2'-fluoro-3'-O-(L-valinyl)cytidine dihydrochloride 5'-deoxy-5'-{4-[2-(3-oxo-3H-benzo[f]chromen-1-yl)acetamidomethyl]-1H-1,2,3-triazol-1-yl}thymidine N6-benzoyl-3'-O-t-butyldimethylsilyl-5'-sulfamoylazido-2',5'-dideoxyadenosine N-{9-[(2R,4S,5R)-5-(Acetylamino-methyl)-4-hydroxy-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide